Free Trial

Lonza Group (LZAGY) Stock Forecast & Price Target

Lonza Group logo
$58.86 -0.71 (-1.19%)
As of 01/14/2025 03:52 PM Eastern

Lonza Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
4

Based on 4 Wall Street analysts who have issued ratings for Lonza Group in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 4 analysts, 1 has given a buy rating, and 3 have given a strong buy rating for LZAGY.

Consensus Price Target

N/A

Get the Latest News and Ratings for LZAGY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Lonza Group and its competitors.

Sign Up

LZAGY Analyst Ratings Over Time

TypeCurrent Forecast
1/16/24 to 1/15/25
1 Month Ago
12/17/23 to 12/16/24
3 Months Ago
10/18/23 to 10/17/24
1 Year Ago
1/16/23 to 1/16/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Strong Buy
Strong Buy
Strong Buy
Moderate Buy

LZAGY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LZAGY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Lonza Group Stock vs. The Competition

TypeLonza GroupMedical CompaniesS&P 500
Consensus Rating Score
3.75
2.82
2.52
Consensus RatingStrong BuyModerate BuyModerate Buy
Predicted UpsideN/A24,950.28% Upside14.85% Upside
News Sentiment Rating
Neutral News

See Recent LZAGY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/27/2024Redburn Atlantic
5 of 5 stars
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/9/2024The Goldman Sachs Group
3 of 5 stars
J. Quigley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/23/2024Berenberg Bank
2 of 5 stars
S. Bray
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/9/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
5/17/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
2/10/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kreger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:41 AM ET.


Should I Buy Lonza Group Stock? LZAGY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 5, 2025. Please send any questions or comments about these Lonza Group pros and cons to contact@marketbeat.com.

Lonza Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Lonza Group AG:

  • Recent upgrades from major analysts, including a "strong-buy" rating from both Goldman Sachs and Redburn Atlantic, indicate strong confidence in the company's future performance.
  • The current stock price of $59.24 reflects a significant increase from its 12-month low of $36.71, suggesting a positive trend in market perception.
  • Lonza Group AG operates in diverse segments such as Biologics and Cell & Gene, which are critical areas in the pharmaceutical and biotech industries, providing multiple revenue streams.
  • A dramatic decrease in short interest by 98.9% in November suggests that investor sentiment is shifting positively, reducing the likelihood of a short squeeze.
  • The company has a solid earnings estimate of $1.66 per share for FY2025, which is slightly above the consensus estimate, indicating potential for growth in profitability.

Lonza Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Lonza Group AG for these reasons:

  • William Blair recently reduced its earnings estimates for FY2025 from $1.78 to $1.66 per share, which may signal concerns about the company's growth prospects.
  • The stock has experienced volatility, with a 52-week high of $67.00 and a current price of $59.24, indicating potential uncertainty in its market performance.
  • Despite the positive analyst ratings, the significant drop in short interest could also reflect a lack of confidence among some investors, who may be anticipating further declines.
  • Lonza Group AG's stock has a relatively high average trading volume, which can lead to increased volatility and risk for investors looking for stability.
  • Market conditions in the pharmaceutical and biotech sectors can be unpredictable, and any adverse developments in these industries could negatively impact Lonza Group AG's performance.

LZAGY Forecast - Frequently Asked Questions

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lonza Group in the last year. There is currently 1 buy rating and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" LZAGY shares.

According to analysts, Lonza Group's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Lonza Group's stock had 1 upgrade by analysts.

Lonza Group has been rated by research analysts at Redburn Atlantic in the past 90 days.

Analysts like Lonza Group more than other "medical" companies. The consensus rating for Lonza Group is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LZAGY compares to other companies.


This page (OTCMKTS:LZAGY) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners